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Introduction
•   Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC) that is approved for the treatment/
secondary prevention of acute venous thromboembolism (VTE; deep vein thrombosis [DVT] and/or 
pulmonary embolism [PE]) in adults, based on its comparable efficacy and superior safety compared 
with warfarin in a broad spectrum of patients with VTE during the Hokusai-VTE trial1  
•   Although randomised controlled trials are the gold standard for comparing treatments and interventions, 
real world evidence (RWE) provides a better representation of the range and distribution of patients and 
management patterns in clinical practice
    –  Consequently, RWE should be used to complement RCT data to establish whether the results 
observed in RCTs are applicable to community practice
•   ETNA-VTE-Europe (NCT02943993) was initiated in agreement with the European Medicines Agency (EMA) 
to assess benefits and risks of edoxaban in the treatment and secondary prevention of VTE for up to  
18 months in routine clinical practice
•   Using an observational study design, we aimed to compare Hokusai-VTE patients with those treated 
in clinical practice during ETNA-VTE Europe, and to expand the knowledge about edoxaban’s clinical 
effectiveness and safety in the treatment and prevention of VTE
Methods
•   ETNA-VTE-Europe is a prospective, non-interventional post-authorisation safety study conducted in 
eight European countries4
•   The study included patients with an initial or recurrent acute VTE that occurred ≤2 weeks prior to 
enrolment and in which a decision (at the treating physician’s discretion) to use edoxaban had already 
been made
•   Descriptive comparisons of Hokusai-VTE and ETNA-VTE Europe are presented
•   Exploratory comparisons between subgroups (DVT vs PE ± PE)  were performed using a Chi-square 
test for categorical variables and a Wilcoxon test for continuous variables  
Results
•   A total of 2879 patients presenting with acute VTE (median age 65 years, 46.5% female) were enrolled 
at 339 sites (133 office-based physicians and 206 hospitals)
•   Of the 2680 patients with complete data, 23.6% reported prior VTE, 2.9% prior stroke, and 2.8% had a 
history of bleeding (Table 1)
•   Patients in ETNA-VTE were older (65 versus 57 years), more likely to be female (46.5% versus 39.8%) 
and had a higher prevalence of chronic venous insufficiency (11.1% versus 1.6%) than in the European 
cohort of the Hokusai-VTE clinical trial (n=1512; Table 1)
    –  Body weight and creatinine clearance (CrCl) were notably lower in clinical practice; more patients had 
a body weight ≤60 kg (9.3% vs 5.6%) and a CrCl ≤50 ml/min (10.2% vs 4.1%)
•   In ETNA-VTE, 90.1% of edoxaban dosing was adherent to the label (Figure 1)
    –  6.6% of patients qualifying for dose reduction were incorrectly prescribed edoxaban 60 mg
    –  3.3% of patients were dose-reduced to 30 mg without a formal indication to do so
•   Heparin lead-in was used in 84.7% of patients and was more frequently used in PE than DVT patients 
(91.3% vs. 80.1%; p<0.0001)
Table 1. Patient characteristics from ETNA-VTE (overall and by VTE presentation) and the Hokusai-VTE 
clinical trial
Parameter HOKUSAI-VTE*
†
N=1512
ETNA-VTE 
N=2680
ETNA-VTE
DVT only 
N=1559
ETNA-VTE
PE ± DVT 
N=1121
p-value  
DVT vs. PE
Age, years 57 (45–69) 65 (52–76) 64 (51–75) 66 (54–76) 0.0052
Female patients 601 (39.8) 1246 (46.5) 706 (45.3) 540 (48.2) 0.1577
Body weight, kg 84.0 (73.9–95.3) 80 (70–92) 80 (70–90) 81 (70–94) 0.0031
Acute VTE diagnosis
   DVT only
   PE with or without DVT
854 (56.5)
658 (43.5)
1559 (58.2)
1121 (41.8)
1559 (100.0)
0 (0.0)
0 (0.0)
1121 (100.0)
N/A
N/A
Hypertension 563 (37.3%) 1150 (42.9) 627 (40.2) 523 (46.7) 0.0006
Medical history
   Diabetes mellitus
   Chronic Venous Insufficiency
   Cancer
   Stroke
115 (7.6)
24 (1.6)
136 (9.0)
18 (1.2)
298 (11.1)
297 (11.1)
253 (9.4)
79 (2.9)
168 (10.8)
214 (13.7)
132 (8.5)
29 (1.9)
130 (11.6)
83 (7.4)
120 (10.7)
50 (4.5)
0.4561
<0.0001
0.0566
0.0001
Bleeding history N/A 76 (2.8) 29 (1.9) 47 (4.2) 0.0003
Frailty N/A 330 (12.3) 176 (11.3) 154 (13.8) 0.0196
CrCL‡,§, ml/min 104.3 (79.0–128.9) 90.1 (65.7–117.7) 91.2 (65.5–120.4) 89.3 (65.9–115.0) 0.2238
VTE history
   Prior DVT
   Prior PE (with or without DVT)
180 (11.8)
107 (7.1)
434 (16.2)
199 (7.4)
310 (19.9)
73 (4.7)
124 (11.1)
126 (11.2)
<0.0001
<0.0001
Edoxaban dose, 60 mg 1371 (90.7) 2351 (87.7) 1349 (86.5) 1002 (89.4) 0.0317
Values are n (%) or medians with IQRs; N/A, not available from the HOKUSAI-VTE dataset or incompatible definition; a Chi-square test was used for categorical variables 
and a Wilcoxon test for continuous variables. Note that the HOKUSAI-VTE population was confined those enrolled in Europe and those receiving Edoxaban. Frailty was 
not further defined in the observational plan and instead based on physician definition.*Only corresponding ETNA-VTE European countries were included in the reported 
Hokusai-VTE cohort (Germany, Austria, Ireland, Netherlands, Italy, Switzerland, Great Britain, Belgium); †mITT and safety population including edoxaban and warfarin 
patients; ‡Recalculated based on patient variables; §Cockroft-Gault formula. CrCl, creatinine clearance; DVT, deep vein thrombosis; PE, pulmonary embolism;  
VTE, venous thromboembolism 
Figure 1. Dosing according to edoxaban label based on bodyweight, creatinine clearance and  
P-gp inhibitor use
Presented at International Society on Thrombosis and Haemostasis 2020, Virtual Congress; 12th – 14th July 2020
•   Based on the proportions of patients fulfilling the dose reduction criteria for edoxaban (Table 2), use of 
edoxaban 30 mg was in line with the SmPC5 in 241 of the 329 (73.3%) patients that were prescribed a 
30 mg dose
Table 2. Patients fulfilling the dose reduction criteria for edoxaban 
Body weight  
≤60 kg
CrCl*,†  
≤50 ml/min
Any of Body weight,  
CrCl or PgP use
Total (N=2680)
  Belgium, Netherlands, Luxembourg (N=692)
  Austria, Germany, Switzerland (N=1012)
  Italy (N=847)
  Ireland/UK (N=129)
241 (9.3)
43 (6.6)
73 (7.4)
118 (14.0)
7 (5.7)
245 (10.2)
43 (6.9)
77 (9.3)
119 (14.4)
5 (4.4)
419 (15.6)
  76 (11.0)
135 (13.3)
197 (23.3)
11 (8.5)
VTE type
  DVT only (N=1559)
  PE ± DVT (N=1121)
142 (9.3)
99 (9.1)
133 (10.0)
112 (10.5)
241 (15.5)
178 (15.9)
Dosing
  30 mg (N=329)
  60 mg (N=2351)
130 (39.9)
111 (4.9)
165 (53.1)
80 (3.8)
241 (73.3)
178 (7.6)
Values are n (%); PgP inhibitor use was not reported due to low number of patients who underwent dose reduction following this criteria (n=2). *Recalculated based 
on patient variables; †Cockroft-Gault formula. CrCl, creatinine clearance; DVT, deep vein thrombosis; PgP, P-glycoprotein; PE, pulmonary embolism; VTE, venous 
thromboembolism
Conclusions
•   The data describe a clinical practice population of VTE patients that is partially different to prior 
randomised controlled trials 
   – The clinical practice population was older and had more comorbidities
•   Edoxaban is largely used adequately in these patients, respecting the recommendations for 
treatment initiation, dosing, and dose adjustments in special patient populations
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